Name

Ochre Bio

Legal name

Ochre Bio Limited

Website

https://ochre-bio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

RNA Therapeutics for Chronic Liver Disease

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

akta.pro secondary industries

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE)

Keywords

• RNA therapeutics
• Chronic liver disease
• Human liver genomics
• Drug discovery platform
• Ex-vivo organ perfusion

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Co-exclusive data and IP licensing: Multi-year co-exclusive license agreement with GSK granting both parties rights to use Ochre-generated proprietary human liver data for AI-driven liver disease drug discovery; includes functional genomics and single-cell datasets.
2. Strategic co-development partnerships with upfront and milestone economics: Approximately $1 billion partnership with Boehringer Ingelheim (announced April 2024) to develop novel regenerative treatments for chronic liver disease; multi-million-pound partnerships with GSK also referenced; model combines upfront payments, R&D funding, and milestone-based economics.
3. Venture capital financing: $9.6M seed (June 2021, led by Khosla Ventures) and $30M Series A (October 2022) used to advance RNA therapy pipeline and platform expansion; capital not core revenue but funds operations.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Ochre Bio develops RNA therapeutics for chronic liver disease using an integrated platform combining proprietary human liver genomics datasets (gene perturbation atlases and patient disease atlases), AI-driven causal target identification via OBELiX software, and ex-vivo validation on perfused human donor livers at its NYC Liver ICU laboratory. The company operates across drug discovery (Human Discovery Platform), late-stage validation (Human Validation Platform), and in-house RNA chemistry (RNA Platform), and out-licenses or co-develops its pipeline through partnerships with major pharmaceutical companies such as GSK and Boehringer Ingelheim.

Product overview

Ochre Bio operates an integrated platform-plus-pipeline architecture for chronic liver disease drug discovery. Its core offering is the Human Discovery Platform (large-scale human liver datasets including gene perturbation atlases and patient disease atlases), supported by the Human Validation Platform (AI combined with perfused human livers, diseased tissue slices, and primary cells) and the proprietary RNA Platform (in-house RNA therapy design and manufacture). These platforms together generate and progress a pipeline of RNA therapeutic candidates — including lead candidate OB-220 (cytoprotection mechanism for significant fibrosis) — alongside partnered programs (e.g., the Boehringer Ingelheim collaboration targeting cirrhosis via regeneration). OBELiX, Ochre's proprietary software, is the unifying computational layer that integrates the company's datasets with disease atlases for causal mapping of gene function to disease signatures.

Differentiator

Problem solved

Functional benefit

Products and services

• OB-220 Internal lead RNA therapeutic development candidate targeting Significant Fibrosis in chronic liver disease via a Cytoprotection mechanism; currently at the Development Candidate stage and progressing toward IND-enabling studies as an internal program.
• Cirrhosis (F4 MASH) Program RNA therapeutic pipeline program targeting Cirrhosis (F4 MASH) via a metabolic mechanism; currently at Lead Development stage as an internal Ochre Bio program advancing toward candidate selection.
• Cirrhosis Regeneration Program RNA therapeutic co-development program with Boehringer Ingelheim targeting Cirrhosis via a regeneration mechanism; part of an approximately $1B strategic partnership announced April 22, 2024 to develop novel regenerative treatments for patients with advanced liver disease.
• Human Liver Functional Genomics Dataset Proprietary large-scale functional genomics dataset generated from primary human hepatocytes (systematic knockdown of all known hepatocyte genes across multiple donors with RNA-seq profiling), licensed to pharmaceutical partners (GSK) under a multi-year co-exclusive data license for AI-driven liver disease target discovery.
• Human Liver Single-Cell Dataset Proprietary single-cell dataset generated from perfused human donor livers at Ochre Bio's NYC Liver ICU laboratory, licensed to pharmaceutical partners (GSK) under a multi-year co-exclusive data license for AI-driven liver disease target discovery.
• Liver ICU Lab (NYC) Validation Services Late-stage validation service operated from the world's largest ex-vivo machine perfusion laboratory of human donor livers at Alexandria Center for Life Science NYC, offering testing of drug candidates on live human donor livers under near-physiological conditions prior to clinical trials.

Quantifiable outcome

• R&D cycle reduced from years to weeks via in-house RNA chemistry platform
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability7 records

Feature7 records

Partnerships

Five partnerships are on record, tiered flagship and core.

• GSKflagshipStrategic or Co-development Partner · 12 June 2024AI/data pact announced June 12, 2024 to pinpoint sources of liver diseases. Delivered two comprehensive functional genomics and single-cell human liver datasets in November 2025; multi-year co-exclusive license agreement grants both parties ability to use Ochre-generated proprietary human liver data for AI-driven discovery. Quote from Kim Branson (SVP, Global Head of AI/ML, GSK) confirms foundational data for AI models.
• Boehringer IngelheimflagshipStrategic or Co-development Partner · 22 April 2024Approximately $1 billion partnership announced April 22, 2024 to develop novel regenerative treatments for patients with advanced liver disease. Targets cirrhosis via a regeneration mechanism. Quote from Søren Tullin (SVP, Global Head of Cardiometabolic Diseases Research, BI) highlights Ochre's unique capabilities in liver disease research and uncovering novel pathways.
• OrganOxcoreTechnology or IntegrationTechnology partner for organ perfusion; logo displayed on Ochre Bio website Partners & Investors section. Likely supplies the ex-vivo machine perfusion platform used in Ochre's NYC Liver ICU laboratory.
• XVIVOcoreTechnology or IntegrationOrgan/tissue technology partner; logo displayed on Ochre Bio website Partners & Investors section. Supports ex-vivo organ perfusion and tissue handling capabilities underpinning Ochre's Liver ICU and tissue labs.
• Alexandria Real Estate EquitiescoreOthersReal estate and life science campus partner. Ochre Bio relocated to Alexandria Center for Life Science – NYC (430 East 29th St) in July 2025 under a JLL-arranged sublease for 5,894 sq ft on the sixth floor of the West Tower, housing late-stage validation facilities and the world's largest ex-vivo machine perfusion laboratory of human donor livers.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• HepaRegeniX: HepaRegeniX is a German preclinical-stage biotech developing small-molecule and RNA approaches to liver regeneration, targeting chronic liver disease and surgical resection settings. Directly comparable to Ochre's Boehringer-partnered cirrhosis regeneration program and shares the same liver-regeneration thesis, though it relies on small molecules rather than ex-vivo human liver validation.
• MiNA Therapeutics: MiNA Therapeutics is a UK-based clinical-stage RNA therapeutics platform company pioneering saRNA (small activating RNA) for liver and metabolic diseases. Closest direct peer to Ochre in RNA modality and liver focus, though MiNA is already in clinical trials while Ochre remains pre-IND.
• Airna Bio: Airna is an RNA editing biotech developing liver-directed oligonucleotide therapies for metabolic and liver diseases. Closely comparable in RNA modality, liver focus, and partnership-driven biotech model; represents the emerging peer set using RNA-based modalities to address indications overlapping with Ochre's pipeline.
• Insitro: Insitro is a US-based AI-driven drug discovery company combining machine learning with high-throughput biology to discover novel therapeutics. Comparable to Ochre in its AI + proprietary-data platform approach to pharma partnerships, though Insitro operates across multiple therapeutic areas and is at later clinical stage.

Broad incumbents

• Recursion Pharmaceuticals: Recursion is a clinical-stage AI drug discovery company using high-throughput biology and ML across multiple therapeutic areas. Comparable as an AI-native drug discovery platform pursuing pharma partnerships, though much larger and more diversified than Ochre's liver-focused scope.
• Madrigal Pharmaceuticals: Madrigal is a commercial-stage biopharma company that secured FDA approval of Rezdiffra (resmetirom) for MASH — the first approved therapy for the indication. Comparable as a liver/MASH-focused biotech; represents the incumbent commercial benchmark Ochre's pipeline candidates would eventually compete against.
• Akero Therapeutics: Akero is a clinical-stage biopharma developing efruxifermin (an FGF21 analog) for MASH and compensated cirrhosis. Comparable as a late-stage liver/MASH-focused biotech; one of several well-funded pure-plays targeting indications overlapping with Ochre's fibrosis and cirrhosis programs.
• Genfit: Genfit is a French biopharma focused on MASH and other metabolic liver diseases, with both internal pipeline assets and diagnostic products (NIS4). Comparable as a European-listed liver-disease specialist and a potential competitor/partner for liver indications Ochre is targeting.
• Viking Therapeutics: Viking Therapeutics is a US clinical-stage biopharma with metabolic disease programs including VK2809 for MASH and VK2735 for obesity. Comparable as a metabolic/liver-focused biotech with multiple clinical assets; represents the broader competitive set for liver indications in the MASH/NASH space.
• Alnylam Pharmaceuticals: Alnylam is the leading clinical and commercial RNA interference (RNAi) therapeutics company, with approved products (Onpattro, Givlaari, Oxlumo, Amvuttra) including liver-directed siRNA therapies. Comparable as the broad incumbent in RNA therapeutics, particularly for liver-targeted indications, and a potential long-term partner or acquirer of platforms like Ochre's.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ochre-bio
• Xx.com/OchreBio

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds4 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ochre Bio